Iovance Biotherapeutics Inc. released a corporate presentation highlighting its leadership in the development and commercialization of tumor infiltrating lymphocyte $(TIL)$ therapies for cancer patients. The company reported that more than 1,000 commercial and clinical patients have been treated with its TIL products, including Amtagvi, which has received approval in the U.S. and Canada. Iovance disclosed prior 12-month product revenue of approximately $250 million and a workforce of about 1,000 employees. The presentation detailed a global advanced melanoma patient treatment opportunity exceeding 70,000 individuals and noted regulatory filings under review in the UK and Australia. Iovance's pipeline includes registrational programs in melanoma and non-small cell lung cancer, as well as next-generation TIL products and ongoing clinical trials. The company reported a cash position of roughly $307 million as of the end of the third quarter of 2025. You can access the full presentation through the link below.